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Antibiotics in the Management of Shigellosis in Children: 
What Role for the Quinolones? 
Olivier Fontaine From the World Health Organization. Diarrhoeal Diseases 
Control Programme, Geneva, Switzerland 
In the last 20 years, epidemic bacillary dysentery due to Shigella dysenteriue type I has 
become an important cause of serious morbidity and death in children less than 5 years 
of age in a number of developing countries; in many instances the infecting strains have 
been resistant to many or all of the usually recommended antibiotics. Moreover, an in- 
creasing proportion of Shigella strains of other serotypes isolated in all parts of the world 
are now resistant to the most commonly used antibiotics. The new fluoroquinolones have 
been shown to be active against Shigelra in vitro and effective for the treatment of shigel- 
losis in adults, but concern about the safety of quinolones has so far prevented the evalu- 
ation of these agents for the treatment of shigellosis in young children. Two observations, 
however, have led a Scientific Working Group of the World Health Organization to sug- 
gest that such studies would be appropriate for the following reasons: a one- or two-dose 
treatment is likely to be effective, and if so the amount of drug given would be far below 
the doses that have been determined to be toxic in animals; and nalidixic acid, which 
shares all the toxicity of the fluoroquinolones. is widely recommended - and in some areas 
routinely used- for the treatment of shigellosis in young children without reports of sig- 
nificant adverse effects. In the Group’s view there is an urgent need to perform carefully 
conducted research to determine the safety and efficacy of fluoroquinolones for the treat- 
ment of shigellosis in children. 
Shigellosis is an acute inflammatory disease of the 
gastrointestinal tract caused by bacteria belonging 
to the genus Shigella and characterized by fever, ab- 
dominal cramping pain, and loose stools, which may 
contain mucus, pus, and blood; however, some pa- 
tients develop only acute, nonspecific watery diar- 
rhea. Bacillary dysentery can also be caused by other 
enteric pathogens, especially Campylobacfer, en- 
teroinvasive Escherichia coli, and enterohemorrhagic 
E. coli. However, the only organism causing dysen- 
tery that is frequently associated with clinically se- 
vere disease that may result in death is Shigella. Since 
visible blood in the stool generally indicates a more 
severe form of the disease, this symptom has gener- 
ally been chosen as the marker for recognition of 
clinically important bacillary dysentery. 
Shigellosis has a global distribution; because the 
infection is transmitted by the fecal-oral route, the 
prevalence of the disease is highest in countries where 
hygiene and sanitation are poor. As few as 10-100 
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viable Shigella can cause the disease in adult volun- 
teers; this probably explains why person-to-person 
transmission is the most common mode of spread 
of this disease. 
Morbidity and Mortality Due to Shigellosis 
During the last 20 years, endemic shigellosis (most 
often due to Shigellajl’exneri or Shigella boydii) and 
epidemic shigellosis (most often due to Shigella 
dysenreriae type 1) have been recognized as impor- 
tant causes of morbidity and death in children <5 
years of age in many developing countries. In Ban- 
gladesh, a survey of patients hospitalized at the In- 
ternational Center for Diarrheal Diseases Research 
(ICDDR,B) in Dhaka over a 14-year period showed 
that 21% of all patients with bacillary dysentery due 
to Shigella were <I year old and that 44% were from 
1 to 4 years old [I]. A community-based survey car- 
ried out in a rural area of Bangladesh showed that 
30% of cases of culture-proven shigellosis occurred 
in children <5 years old and 54% in children <10 
years old [21. 
No data concerning mortality rates due to dysen- 
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tery are available from community-based studies. 
However, before the widespread implementation of 
oral rehydration therapy (ORT) for watery dehydrat- 
ing diarrhea, it was estimated that shigellosis ac- 
counted for 15% of diarrheal deaths. As the use of 
ORT increases and deaths due to acute dehydration 
decline, this percentage would inevitably rise. 
In patients hospitalized for shigellosis, reported 
mortality rates are between 1% and lo%, depend- 
ing on the epidemiologic situation [3,4]. During the 
1972-1978 epidemic due to S. dysenteriae type 1, the 
case-fatality rate at the well-equipped hospital of the 
ICDDR,B was mlO%; in contrast, the case-fatality 
rate for cholera in the same hospital was m0.5% dur- 
ing the same period. 
Shigellosis is more frequently severe in young chil- 
dren, as shown by the case-fatality rates observed in 
4 years (1969,1974,1980, and 1982) at the ICDDR,B 
hospital (table 1). In fact, 87% of the deaths in pa- 
tients admitted to the hospital with shigellosis oc- 
curred in children <5 years of age, and 96% in chil- 
dren <10 years of age [l]. 
Risk factors that characterize children at  highest 
risk of death from dysentery have been identified 
in several studies [4, 51. These factors are summa- 
rized as follows: (1) malnutrition- severely mal- 
nourished children (i.e., those for whom the ratio of 
weight for age is <60% of the median of the stan- 
dards of the National Center for Health Statistics) 
have a three- to sevenfold increased risk of dying, 
compared with better nourished children; (2)  age- 
children with shigellosis who are <1 year old have 
a threefold increased risk of dying compared with 
children who are >1 year old; (3) children who have 
not been breast-fed; (4) moderate or severe dehydra- 
tion at presentation; (5) absence of fever at presen- 
tation; (6) presence of bacteremia; and (7) persistent 
diarrhea (i.e., an episode of diarrhea lasting for >2 
weeks). 
It has been shown that among all diarrheal epi- 
Table 1. 
with shigellosis. 
Age group rate ('%) 
Case-fatality rate for children hospitalized 
---- 
Case-fatality 
<1 Y 13.8 
1-4 y 8.3 
5-9 y 5.1 
210 y O. I 
NOTE. Data are from [I]. 
sodes of known etiology, shigellosis has the greatest 
negative impact on linear growth [6] .  It was found 
that diarrheal episodes due to Shigella lastled longer 
than other types of diarrhea and caused greater losses 
of serum protein. Moreover, the problem of protein 
loss is exacerbated by poor dietary intake as a result 
of prolonged anorexia. 
From the preceding, icis apparent that prevention 
or effective treatment of shigellosis would not only 
diminish mortality due to diarrhea but should also 
have a significant positive impact on growth and 
nutritional status. 
Antibiotic Resistance 
When combined with appropriate dietary manage- 
ment, ORT, which can prevent or treat clinically evi- 
dent dehydration, is the basis for effective treatment 
of acute watery diarrhea. In shigellosis, holwever, an- 
tibiotics are required. When appropriately used, an- 
tibiotics have been shown to substantially reduce 
the severity of the illness and to shorten its duration 
Some of the antibacterial agents that have been 
used to treat shigellosis are tetracycline (single or mul- 
tiple doses), ampicillin (single or multiple doses), 
t rimethoprim-sulfamet hoxazole (TM P-SMZ; muh i- 
ple doses for 5 days), nalidixic acid (multiple dose 
for 5 days), trimethoprim alone (multiple doses for 
5 days), chloramphenicol, and ceftriaxone (intra- 
venous). 
The effectiveness of these agents has, however, 
been seriously impaired by the widespread emergence 
of bacterial resistance-often to multiple antibiot- 
ics -especially in S. dysenteriae type 1. Tetracyclines 
were the first widely used effective antibiotics ad- 
ministered in a single dose (2.5 g) or mulltiple doses 
over a 3- to 5-day period [IO]. When Shigella devel- 
oped resistance to tetracyclines, ampicillin became 
the drug of choice; however, in the early 1980s 
ampicillin-resistant strains appeared and became 
widespread in Asii [Il] and Africa [12]. TMP-SMZ 
then became the drug of choice. However, shortly 
after it assumed this role, resistance appeared; for 
example, in 1980 100% of Shigella strains isolated 
in Dhaka, Bangladesh, were sensitive to TMP-SMZ, 
whereas 4 years later only 45% were sensitive [ll].  
These changing patterns of sensitivity were well 
illustrated during a recent epidemic of S. dysenter- 
iue type U in Central Africa. At the beginning of the 
epidemic in 1980, the first isolates were already resis- 
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tant to ampicillin, tetracyclines, chloramphenicol, 
and sulfonamides; therefore, TMP-SMZ was widely 
used as therapy. By 1982, resistance to TMP-SMZ 
had become a major problem, occurring almost 
equally in both epidemic and endemic strains. 
The emergence of strains resistant to the three ma- 
jor antimicrobial agents (tetracycline, ampicillin, and 
TMP-SMZ) led to the use of nalidixic acid, although 
evidence of its efficacy, based on results of controlled 
studies, was scanty. Indeed, a study performed in 
1973 [13] had shown that although nalidixic acid was 
effective in vitro against most strains of Shigella, 
stool cultures remained positive longer in patients 
who received nalidixic acid than in those who re- 
ceived ampicillin, and the clinical response was 
slower. In fact, the authors concluded that “nalidixic 
acid had little effect on the course of the disease.” 
Nevertheless, nalidixic acid is now being used for the 
initial treatment of shigellosis in many countries 
where strains resistant to other antibiotics are com- 
monly encountered (eg., Bangladesh, India, Rwanda). 
The need for more effective antimicrobial agents 
for the treatment of shigellosis is evident. The Diar- 
rhoeal Diseases Control (CDD) Programme of the 
World Health Organization has therefore made one 
of its research priorities the identification of alter- 
native antibiotics for use in the treatment of shigel- 
losis in young children in areas where severe illness 
due to strains resistant to ampicillin and TMP-SMZ 
occurs. Some of the drugs now under consideration 
are as follows: 
Nearly all Shigella strains 
are sensitive to gentamicin in vitro; however, this drug 
is not absorbed from the gastrointestinal tract, and 
it is not likely that therapeutic concentrations of the 
drug are attained in the bowel wall. In China, oral 
gentamicin is considered effective and widely used; 
however, there are no controlled studies that estab- 
lish its efficacy. 
(2 )  Pivmecillinam. This penicillin analogue, 
given orally, has been shown to be effective for the 
treatment of adults with shigellosis in Bangladesh 
(3) Bicozamycin. This is a nonabsorbable antibi- 
otic with a wide spectrum of activity against gram- 
negative enteric organisms and no relationship to 
other widely used antibiotics. Despite its being 
nonabsorbable, bicozamycin was shown to be effec- 
tive in treating ’diarrhea due to Shigella in adult 
travelers [15]. However, bicozamycin is not marketed 
at  present. 
( I )  Oral gentamicin. 
(141. 
(4)  Doxycycline. A single study has shown that 
adults infected with tetracycline-resistant Shigella 
(resistant to 12.5 mg/L) responded adequately to 
treatment with a single large oral dose (2.5 g) of 
tetracycline [lo]. The possibility that doxycycline, a 
long-acting tetracycline, given in a single dose may 
be effective even for antibiotic-resistant strains should 
be explored. 
(5) Fluoroquinolones. 
The Fluoroquinolones 
The new quinolone antibiotics (fluoroquinolones) 
are closely related to nalidixic acid and have been 
shown to be highly effective in vitro against Shigella. 
The MIC,, and MIC,, of nalidixic acid and of five 
fluoroquinolones for Shigella are compared in ta- 
ble 2 [Ití]. This table shows that the new quinolones 
are highly active in vitro against Shigella. Norfloxa- 
cin and ciprofloxacin seem to be less completely ab- 
sorbed from the gastrointestinal tract than are the 
other fluoroquinolones; these two antibiotics have 
also been reported to achieve a high concentration 
in stools (773 mg/L for norfloxacin and 891 mg/L 
for ciprofloxacin) [17]. In addition, 48 hours after 
a single 400” oral dose of norfloxacin, a high level 
of theantibiotic (>40 pg/g) remains in the feces [IS]. 
For these reasons, norfloxacin and ciprofloxacin 
appear to be promising agents for use in the treat- 
ment of shigellosis. The high concentration of the 
drug still present in the feces 48 hours after a single 
400-mg oral dose leads us to consider that single- 
dose therapy (or perhaps a daily dose given for 2 
days) might be effective for the treatment of shigel- 
losis. A simple treatment regimen of this type would 
be advantageous for the provision of effective ther- 
apy under conditions where the reliable delivery of 
medication for a longer period is very difficult. 
Clinical studies with oral fluoroquinolones mostly 
Table 2. 
quinolones and nalidixic acid. 
In vitro activity against ShigeUa of 5-fluoro- 
Concentration (mg/L) 
Comoound MICw M IC., 
Nalidixic acid 
Norfloxacin 
Ciprofloxacin 
Ofloxacin 
Enoxacin 
Pefloxacin 
4.0 
0.03 
0.02 
o. 1 
o. 1 
0.06 
4.0 ~ 
0.03 
0.02 
o. 1 
0.2, 
0.06 
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concern the use of these drugs in infections of the 
genitourinary tract. One published study, however, 
compared the efficacy of norfloxacin vs. nalidixic 
acid in the treatment of adults with shigellosis dur- 
ing an epidemic in Rwanda due to S. dysenferiae type 
1 [19]. The results of this study suggest that norflox- 
acin is superior t o  nalidixic acid with respect to clin- 
ical response and elimination of Shigella from the 
stools. However, because of the limited number of 
patients treated in this study and because it was not 
controlled, no definite conclusions could be drawn. 
Other studies of adults have shown that Shigella was 
eradicated within 48 hours after the administration 
of norfloxacin and that the clinical response in pa- 
tients receiving norfloxacin was similar to  that ob- 
served in patients receiving TMP-SMZ [18, 201. 
As mentioned above, the new quinolones are 
closely related to nalidixic acid and therefore also 
share the toxicities of that drug, including effects on 
the CNS (lightheadedness, headache, drowsiness, 
and insomnia); cutaneous reactions (skin rash and 
pruritus, phototoxic reactions ranging from mild er- 
ythema in areas exposed to the sun to extensive bul- 
lous eruptions that mimic porphyria [21]); and rheu- 
matologic symptoms (swelling and stiffness of the 
joints, arthralgia, myalgia [17, 211). 
However, the number of adverse effects reported 
to date among patients treated with fluoroquinolones 
appears to be low (5%-25%); therapy has been dis- 
continued as a result of development of adverse reac- 
tions in only 1%-3% of patients [21]. 
Toxicity to cartilage, known to be a characteristic 
of nalidixic acid, has also been reported in animals 
treated with fluoroquinolones. This toxicity includes 
inhibition of the growth of juvenile cartilage; inhi- 
bition of the growth of cartilaginous limb buds in 
embryonic mice; and erosions of the articular carti- 
lage, with hypertrophy and eosinophilia of the chon- 
drocytes, in dogs given high doses of nalidixic, oxo- 
h i c ,  or pipemidic acids (200-350 mg/kg) [22-241. 
The relationship of these experimental results to 
the rheumatologic symptoms observed in patients 
treated with nalidixic acid is still uncertain. Indeed, 
nalidixic acid has been used for years for the treat- 
ment of  childhood infections without any report of 
secondary arthropathy [25,26]. Arthropathies have 
been reported in patients being treated with the newer 
quinolones [17], but these patients were all receiv- 
ing long-term therapy for chronic infection. The ad- 
verse effects, including the rheumatologic symptoms, 
observed with the newer quinolones all regressed 
when therapy was discontinued, without any need 
for additional specific treatment. 
However, because the toxic effect on bone and car- 
tilage of the newer quinolones is an important con- 
cern, fluoroquinolones have not yet been recom- 
mended for routine use in pregnant women and in 
children <15 years of age, whose skeletal growth is 
incomplete. 
Consideration of the Use of Fluoroquinolones 
to Treat Shigellosis in Young Children 
Concern about the safety of fluoroquinolones has 
until now prevented the evaluation of these drugs 
for the treatment of shigellosis in young children. 
However, a review of available information on the 
safety and efficacy of these agents by the Scientific 
Working Group on Case Management of the WHO/ 
CDD Programme suggests that this view may be 
overly cautious for the following reasons: 
(1) There is an evident and urgent need for new 
effective antimicrobial agents for the treatment of 
shigellosis in young children as a result of the wide- 
spread occurrence of strains resistant to available 
agents. 
(2) The new fluoroquinolones have been shown 
to be active in vitro against Shigella (and Campylo- 
bacrer species, another important cause of dysen- 
tery in young children), and limited evidence sug- 
gests that they are also effective in vivo. 
(3) Nalidixic acid, which shares all the cartilage 
toxicity of the fluoroquinolones, is licensed for use 
in children and is widely recommended for the treat- 
ment of shigellosis in young children without any 
report of major adverse effects [28]. 
(4) The occurrence of the rheumatologic symp- 
toms associated with the fluoroquinolones seems IO 
be related to the amount of drug absorbed and the 
duration of treatment. Because of the high concen- 
tration of the drug achieved in the feces after even 
one dose, the amount to be given in a single dose 
or even a 2-day treatment would be far below that 
which causes toxic signs in experimental animals. 
However, a careful monitoring of any adverse effect 
during the treatment and in the months following 
should be performed when using the newer quino- 
Iones in children, especially in children whose cal- 
cium metabolism or growth may be impaired by se- 
rious malnutrition. 
(5) A risk-benefit analysis of the use of fluoro- 
quinolones in children <15 years of age suggests that 
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the risks associated with fluoroquino~one treatment 9. Haltalin KC, Kusmiesz HT, Hinton Lv, Nelson JD. Treat- 
ment of acute diarrhea in outpatients: double-blind study 
comparing ampicillin and placebo. Am J Dis Child in this age group are far outweighed by the benefits 
that effective treatment of this life-threatening dis- 1972:124:554-61 
ease could provide [29]. 
Conclusion 
It is likely that the fluoroquinolones could play an 
important role in the reduction of the morbidity and 
mortality due to shigellosis in young children infected 
with strains that are resistant to conventional anti- 
biotics. Because the drug would probably be ad- 
ministered either as a onedose treatment, or at most 
for 2 days, the amount given would be far below that 
which causes toxic signs in animals. Although this 
reasoning does not constitute a recommendation for 
the routine use of fluoroquinolones for the treatment 
of shigellosis in children, it does suggest that care- 
fully conducted research to determine the safety and 
10. Pickering LK. Dupont HL, OIarte J. Single-dose tetracycline 
therapy for shigellosis in adults. JAMA 1978;239:853-4 
Il. Murray BE. Resistance of Shigella, Salmonella, and other 
selected enteric pathogens to antimicrobial agents. Rev In- 
fect Dis 1986;8(Suppl 2):S172-81 
12. Frost JA, Rowe B. Vandepitte J, Threlfall EJ. Plasmid charac- 
terisation in the investigation of an epidemic caused by 
multiply resistant Shigella dysenteriae, type 1 in Central 
Africa. Lancet 1981;21074-6 
13. Haltalin KC. Nelson JD, Kusmiesz HT. Comparative effi- 
cacy of nalidixic acid and ampicillin for severe shigellosis. 
Arch Dis Child 1973;48:305-12 
14. Kabir I, Rahaman MM. Ahmed SM, Akhter SQ, Butler T. 
Comparative efficacies of pivmecillinam and ampicillin 
in acute shigellosis. Antimicrob Agents Chemother 1984: 
15. Ericsson CD, Dupont HL, Galindo E, Mathewson JJ, Mor- 
gan DR, Wood LV, Mendiola J. Efficacy of bicozamycine 
in preventing traveller's diarrhea. Gastroenterology 
25543-5 
efficacy of these agents should be performed, a view 1985;88:473-7 
also supported by the Scientific Working G~~~~ on 
Case Management of the WHO Programme for 
Control of Dk"-al Diseases. This group has con- 
16. Wolfson JS, Hooper DS. The fluoroquinolones: structures. 
mechanisms of action and resistance, and spectra of ac- 
tivity in vitro. Antimicrob Agents Chemother 1985;28:581-6 
ogy, clinical uses, and toxicities in humans. Antimicrob 
Agents Chemother 1985;28:716-21 
17. Hooper DC. l%lfson JS. The fluoroquinolones: pharmacol- 
cluded that the information derived from such stud- 
ies would contribute substantiallv to efforts to de- 
velop better tools for the control of this important 18. Ruiz-Palacios GM. Norfloxacin in the treatment of bacterial 
enteric infections. Scand J Infect Dis [Suppl] 1986,48:55-63 
19. Roeerie F. Ott D. Vandeoitte J. Verbist L, Lemmens P, cause of morbidity and mortality in children. 
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